Overall Survival and Progression Free Survival in the FRESCO-2 Trial

Arvind Dasari, MD, examines the progression-free survival and overall survival data from the FRESCO-2 trial, comparing the results to the original FRESCO trial, and discussing the implications for the treatment of heavily pretreated metastatic colorectal cancer patients.

Now Viewing

EP: 1.Overall Survival and Progression Free Survival in the FRESCO-2 Trial

EP: 2.FRESCO-2 Study Design Overview

EP: 3.Adverse Event Profile and Tolerability of Fruquintinib Based on FRESCO-2 Trial

Recent Videos